Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 140-148

  Patsalos, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AEDs; Clobazam; Clonazepam; Ethosuximide; IGE; Lamotrigine; Levetiracetam; Topiramate; Zonisamide

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ALBUMIN; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; GLUTAMIC ACID; LAMOTRIGINE; LIVER ENZYME; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; RITONAVIR; SERTRALINE; SUMATRIPTAN; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; PRIORITY JOURNAL; REVIEW; DRUG INTERACTION; METABOLISM;

ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY, GENERALIZED; HUMANS;

EID: 32944467278     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00326.x     Document Type: Review

References (57)

1. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-24.
2. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific GABAA receptor subtypes. Nature 1999;401:796-800.
3. Divoll M, Greenblatt D, Ciraulo D, et al. Clobazam kinetics: intrasubject variability and effect of food on absorption. J Clin Pharmacol 1982;22:69-73.
4. Voltz M, Christ O, Kellner H-M, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol 1979;7(suppl 1):41S-50S.
5. Hanks GW. Clobazam: pharmacological and therapeutic profile. Br J Clin Pharmacol 1979;7(suppl 1):151S-5S.
6. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1982;14:269-74.
7. Berlin A, Dahlstrom H. Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and repeated oral administration. Eur J Clin Pharmacol 1975;9:155-9.
8. Seree EJ, Pisano PJ, Placidi M, et al. Identification of the human and animal hepatic cytochrome P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993;7:69-75.
9. Gomora JC, Daud AN, Weiergraber M, et al. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001;60:1121-32.
10. Buchanan RA, Kinkel AW, Smith TC. The absorption and excretion of ethosuximide. Int J Clin Pharmacol 1973;7:213-8.
11. Battino D, Cusi C, Fraceshetti S, et al. Ethosuximide plasma concentrations: influence of age and associated concomitant therapy. Clin Pharmacokinet 1982;7:176-80.
12. Kuhnz W, Koch S, Jacob S, et al. Epileptic women during pregnancy and lactation: placental transfer, serum concentration in nursed infants and clinical status. Br J Clin Pharmacol 1984;18:671-7.
13. Bachmann KA, Chu CA, Grear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology 1992;45:121-8.
14. Pisani P, Narbone MC, Trunfio C, et al. Valproic acid-ethosuximide interaction: a pharmacokinetic study. Epilepsia 1984;25:229-33.
15. Giaccone M, Bartoli A, Gatti G, et al. Effects of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1996;41:575-9.
16. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993;612:190-9.
17. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997;19:252-60.
18. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1997;42:535-41.
19. Ryan M, Grim SA, Miles MV, et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy 2003;23:1550-7.
20. Eriksson A, Hoppu K, Nergardh A, et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996;37:769-73.
21. Remmel RP, Sinz MW, Graves NM, et al. Lamotrigine and lamotrigine-N-glucuronide concentrations in human blood and brain tissue. Seizure 1992;1(suppl A):7-34.
22. Tomson T, Ohman I, Vitols. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997;38:1039-41.
23. Sinz MW, Remmel RP. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos 1991;19:149-53.
24. Posner J, Holdrich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharmaceut Med 1991;1:121-8.
25. Fillastre JP, Taburet AM, Fialaire A, et al. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993;19:25-32.
26. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;6: 347-56.
27. Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-3.
28. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
29. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-1.
30. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59(2):251-5.
31. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63(3):571-3.
32. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62(2):292-5.
33. Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother 2004;13:1-168.
34. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-6.
35. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
36. Perucca E, Gidal BE, Bates E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive trials. Epilepsy Res 2003;53:47-56.
37. Edwards KR, Glantz MJ, Bator T, et al. Levetiracetam levels in human cerebrospinal fluid: a controlled, dose-ranging pharmacokinetic study. Neurology 2004;62(suppl 5):A118.
38. Greenhill L, Betts T, Yarrow H, et al. Breast milk levels of levetiracetam after delivery. Epilepsia 2004;45(suppl 7):230.
39. Grim SA, Ryan M, Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit 2003;25:61-6.
40. Strolin Benedetti M, Whomsley R, Nicolas JM, et al. Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 2003;59:621-30.
41. Patsalos PN. The mechanism of action of topiramate. Rev Contemp Pharmacother 1999;10:147-53.
42. Patsalos PN. The pharmacokinetic profile of topiramate. Rev Contemp Pharmacother 1999;10:155-62.
43. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43:763-80.
44. Loscher W. Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-94.
45. Franke D, Diletti E, Hoffmann C, et al. Relative bioavailability of different valproic acid formulations. Int Clin Pharmacol Ther 1995;33:653-7.
46. Cramer JA, Mattson RH, Bennett DM, et al. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit 1986;8:411-5.
47. Anari MR, Burton RW Gopaul S, et al. Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry. J Chromatogr B Biomed App 2000;742:217-27.
48. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-9.
49. Armijo JA, Bravo J, Caudrado A, et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999;21:183-90.
50. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks Ttype calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
51. Ito T, Yamaguchi T, Miyazaki H, et al. Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. Arzneimittelforschung 1982;32:1581-6.
52. Taylor CP, McLean JR, Bockbrader HN, et al. Zonisamide. In: Meldrum BS, Porter RJ, eds. New anticonvulsant drugs. London: John Libbey, 1986:277-94.
53. Siedlik P, Brockbader H, Chang T, et al. Effect of food on the oral absorption of zonisamide in normal healthy volunteers. Pharm Res 1986;3(suppl):158S.
54. Wagner J, Sackellares J, Donofrio P, et al. Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984;6:277-83.
55. Matsumoto K, Miyazaki H, Fujii T, et al. Absorption, distribution and excretion of 3-(sulphamoyl[14C]methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimittelforschung 1983;33:961-8.
56. Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986;8:293-6.
57. Patsalos PN. Antiepileptic drug interactions. A clinical guide. Guildford: Clarius Press, 1986.